Enliven Therapeutics, Inc.

(RTTNews) - Enliven Therapeutics, Inc (ELVN) revealed Loss for its second quarter of -$25.34 million
The company's bottom line totaled -$25.34 million, or -$0.49 per share. This compares with -$19.95 million, or -$0.41 per share, last year.
Enliven Therapeutics, Inc earnings at a glance (GAAP) :
-Earnings: -$25.34 Mln. vs. -$19.95 Mln. last year. -EPS: -$0.49 vs. -$0.41 last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Enliven Therapeutics, Inc Q2 Loss Climbs

(RTTNews) - Enliven Therapeutics, Inc. (ELVN), a company focused on the discovery and development of small molecule therapeutics, said on Friday that it has commenced an underwritten public offering of $200 million of shares and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares.
In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares.
All of the shares and pre-funded warrants are being offered by Enliven.
Jefferies, Goldman Sachs & Co. LLC, TD Cowen and Mizuho are acting as joint book-running managers, while LifeSci Capital is acting as lead manager for the proposed offering.
ELVN was down by 2.34% at $19.20 in the pre-market trade on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares

(RTTNews) - Enliven Therapeutics Inc. (ELVN) announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia who have either failed available therapies, are intolerant to them, or are not candidates for these treatments. ELVN-001 continues to show clinical benefit in heavily pretreated chronic myeloid leukemia patients.
According to the company, the updated data includes 39 patients across various dose levels, 18 of whom were evaluable for molecular response by 24 weeks. Consistent with the 12-week results the Company presented in April 2024, a cumulative major molecular response (MMR) rate of 44.4% (8/18) was observed by 24 weeks in response-evaluable chronic myeloid leukemia patients. Additionally, ELVN-001 continues to be well-tolerated with no dose reductions and a median treatment duration of 20 weeks.
With more patients enrolled and longer follow up, the company said it continues to see anti-chronic myeloid leukemia activity in a heavily pre-treated patient population that includes patients previously treated with asciminib. Additionally, ELVN-001's safety profile remains consistent with its high selectivity, even with longer duration and more patients enrolled at higher dose levels.
The company believes the data demonstrate the potential clinical utility of ELVN-001 for patients across the full spectrum of the CML treatment paradigm.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients

Investors eyeing a purchase of Enliven Therapeutics Inc (Symbol: ELVN) shares, but cautious about paying the going market price of $25.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2025 put at the $17.50 strike, which has a bid at the time of this writing of $2.25. Collecting that bid as the premium represents a 12.9% return against the $17.50 commitment, or a 19.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to ELVN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $17.50 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Enliven Therapeutics Inc sees its shares fall 32.5% and the contract is exercised (resulting in a cost basis of $15.25 per share before broker commissions, subtracting the $2.25 from $17.50), the only upside to the put seller is from collecting that premium for the 19.7% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Enliven Therapeutics Inc, and highlighting in green where the $17.50 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the March 2025 put at the $17.50 strike for the 19.7% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Enliven Therapeutics Inc (considering the last 251 trading day closing values as well as today's price of $25.91) to be 83%. For other put options contract ideas at the various different available expirations, visit the ELVN Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Friday, the put volume among S&P 500 components was 1.40M contracts, with call volume at 1.40M, for a put:call ratio of 0.73 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today.
Top YieldBoost Puts of the S&P 500 »
Also see:
Computer Peripherals Dividend Stocks
MKTX YTD Return
Institutional Holders of COGT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Commit To Purchase Enliven Therapeutics At $17.50, Earn 19.7% Annualized Using Options

Investors considering a purchase of Enliven Therapeutics Inc (Symbol: ELVN) stock, but cautious about paying the going market price of $16.61/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $10 strike, which has a bid at the time of this writing of 45 cents. Collecting that bid as the premium represents a 4.5% return against the $10 commitment, or a 11.2% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to ELVN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $10 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Enliven Therapeutics Inc sees its shares fall 39.8% and the contract is exercised (resulting in a cost basis of $9.55 per share before broker commissions, subtracting the 45 cents from $10), the only upside to the put seller is from collecting that premium for the 11.2% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Enliven Therapeutics Inc, and highlighting in green where the $10 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $10 strike for the 11.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Enliven Therapeutics Inc (considering the last 251 trading day closing values as well as today's price of $16.61) to be 82%. For other put options contract ideas at the various different available expirations, visit the ELVN Stock Options page of StockOptionsChannel.com.
Also see:
Low Beta Stocks
FRBK Stock Predictions
Funds Holding WBB
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 23.75
P/B	4.20 2.20
P/FCF	0.00 18.30

Indicator	TTM Median
ROE	-29.35 25.41
ROA	-27.30 6.00
Net Worth	1.31 0.20
Quick Ratio	0.00 1.71
Current Ratio	14.39 2.83

Indicator	TTM Median
EPS	0.48 0.37
EPS Forecast	0.52 0.37
Revenue	0.00 16.00M
Gross Profit	0.00 —
EBITDA	-25.00M —

Enliven Therapeutics, Inc.

Fundamental ELVN

Valuation

Debts

Efficiency

Other ratios

Revenue